ABSTRACT
RATIONALE Persistent cough and dyspnea are prominent features of post-acute sequelae of SARS-CoV-2 (termed ’Long COVID’); however, physiologic measures and clinical features associated with these pulmonary symptoms remain poorly defined.
OBJECTIVES Using longitudinal pulmonary function testing (PFTs) and CT imaging, this study aimed to identify the characteristics and determinants of pulmonary Long COVID.
METHODS The University of Alabama at Birmingham Pulmonary Long COVID cohort was utilized to characterize lung defects in patients with persistent pulmonary symptoms after resolution primary COVID infection. Longitudinal PFTs including total lung capacity (TLC) and diffusion limitation of carbon monoxide (DLCO) were used to evaluate restriction and diffusion impairment over time in this cohort. Analysis of chest CT imaging was used to phenotype the pulmonary Long COVID pathology. Risk factors linked to development of pulmonary Long COVID were estimated using univariate and multivariate logistic regression models.
MEASUREMENTS AND MAIN RESULTS Longitudinal evaluation 929 patients with post-COVID pulmonary symptoms revealed diffusion impairment (DLCO ≤80%) and restriction (TLC ≤80%) in 51% of the cohort (n=479). In multivariable logistic regression analysis (adjusted odds ratio; aOR, 95% confidence interval [CI]), invasive mechanical ventilation during primary infection conferred the greatest increased odds of developing pulmonary Long COVID with diffusion impaired restriction (aOR=10.9 [4.09-28.6]). Finally, a sub-analysis of CT imaging identified evidence of fibrosis in this population.
CONCLUSIONS Persistent diffusion impaired restriction was identified as a key feature of pulmonary Long COVID. Subsequent clinical trials should leverage combined symptomatic and quantitative PFT measurements for more targeted enrollment of pulmonary Long COVID patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute of Allergy and Infectious Diseases (AI156898, K08AI129705), the National Heart, Lung, and Blood Institute (HL153113, OTA21-015E, HL149944), and the COVID-19 Urgent Research Response Fund established by the Hugh Kaul Precision Medicine Network at the University of Alabama at Birmingham. No co-authors have any disclosures.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Dr. Nathaniel Erdmann oversaw and obtained IRB approval from the University of Alabama at Birmingham (UAB IRBs: 300006291, 300006205). The IRB committee of the University of Alabama at Birmingham gave ethical approval for use of the de-identified retrospective cohort data used in this manuscript.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† First Author
↵‡ Co-senior Authors
Michael John Patton, BA, MD,PhD candidate, mjpatton{at}uab.edu, Donald Benson, MD, PhD, donaldbenson{at}uabmc.edu, Sarah W. Robison, MD, srobison{at}uabmc.edu, Raval Dhaval, MD, draval{at}uabmc.edu, Morgan L. Locy, MD, PhD, mllocy{at}uabmc.edu, Kinner Patel, MD, kinnerpatel{at}uabmc.edu, Scott Grumley, MD, sgrumley{at}uabmc.edu, Emily B. Levitan, ScD, emilylevitan{at}uabmc.edu, Peter Morris, MD, pmorris{at}uabmc.edu, Matthew Might, PhD, might{at}uab.edu, Amit Gaggar, MD, PhD, agaggar{at}uabmc.edu, Nathaniel Erdmann, MD, PhD, nberdmann{at}uabmc.edu
Data Availability
For protection of personal health information, data will only be made available with the approval of the University of Alabama at Birmingham IRB committee and the signing of formal data use agreement.
